Pharmacogenomics to improve childhood acute lymphoblastic leukaemia therapy

With current therapy more than 80% of children with acute lymphoblastic leukaemia (ALL) can be cured in industrialized countries. However, ALL is still amongst the leading causes of death from disease in children aged 1–15 years. Of note, antileukaemic medications can cause significant adverse drug...

Full description

Saved in:
Bibliographic Details
Published in:Memo - Magazine of European medical oncology 2009-06, Vol.2 (2), p.65-70
Main Author: Kager, Leo
Format: Article
Language:English
Subjects:
Medicine
Medicine & Public Health
Oncology
Short Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With current therapy more than 80% of children with acute lymphoblastic leukaemia (ALL) can be cured in industrialized countries. However, ALL is still amongst the leading causes of death from disease in children aged 1–15 years. Of note, antileukaemic medications can cause significant adverse drug reactions; and some patients have leukaemia cell clones that are resistant to current antileukaemic treatment. Therefore, further improvement of childhood ALL therapy is urgently needed. Pharmacogenomics aims to elucidate functionally relevant genomic determinants for drug disposition and response to improve drug therapy based on a patient’s genomic profile. Results from recent pharmacogenomic investigations including large-scale genome-wide analyses hold promise to improve ALL therapy in the near future.
ISSN:1865-5041
1865-5076
DOI:10.1007/s12254-009-0110-1